PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

7423312

Reference Type

Journal Article

Title

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

Author(s)

Lehmann, BD; Bauer, JA; Schafer, JM; Pendleton, CS; Tang, L; Johnson, KC; Chen, X; Balko, JM; Gómez, H; Arteaga, CL; Mills, GB; Sanders, ME; Pietenpol, JA; ,

Year

2014

Is Peer Reviewed?

Journal

Breast Cancer Research
ISSN: 1465-5411
EISSN: 1465-542X

Publisher

BMC

Location

LONDON

Volume

Issue

Language

English

PMID

25103565

DOI

10.1186/s13058-014-0406-x

Web of Science Id

WOS:000344310300014

URL

http://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-014-0406-x
Exit

Abstract

Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers, which contributes to variable clinical outcomes. Previously, we identified a TNBC subtype that has a luminal phenotype and expresses the androgen receptor (AR+). TNBC cells derived from these luminal AR + tumors have high frequency phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. The purpose of this study was to determine if targeting phosphoinositide 3-kinase (PI3K) alone or in combination with an AR antagonist is effective in AR + TNBC.